QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer

QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer is a phase 2, interventional study registered as NCT07175636 by Sun Yat-sen University, with a registry enrolment figure of 66 participants, started 2025-09-20 and due to reach its primary completion in 2026-09-20. Interventions recorded: Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT). Conditions listed: Locally Advanced Rectal Cancer (LARC); Mismatch Repair-Proficient (pMMR) Rectal Cancer; Non-metastatic Rectal Cancer. Primary outcome: Pathologic Complete Response (pCR) Rate. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". No results are recorded here; the registry entry is the source.